ResearcherShiraz UniversityNo recent work listed

Motahareh Mortazavi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112976699. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2022.103749 ↗
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases incl… Co-author DOI 10.1038/s41598-021-83069-4 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fatemeh Moosavi · 2 shared papers, 2021–2022 · strength 0.34
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
- Paper Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentiall… DOI 10.1038/s41598-021-83069-4 ↗
Omidreza Firuzi · 2 shared papers, 2021–2022 · strength 0.34
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
- Paper Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentiall… DOI 10.1038/s41598-021-83069-4 ↗
Elisa Giovannetti · 1 shared paper, 2022 · strength 0.20
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
Miriam Martini · 1 shared paper, 2022 · strength 0.20
- Paper Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. DOI 10.1016/j.critrevonc.2022.103749 ↗
Tahereh Damghani · 1 shared paper, 2021 · strength 0.13
- Paper Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentiall… DOI 10.1038/s41598-021-83069-4 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.